Itraconazole, a new triazole that is orally active in aspergillosis.
about
Overview of medically important antifungal azole derivativesEfficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosisRodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children.Antifungal agents of use in animal health--practical applications.In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis.In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agentAzole antifungal agents: emphasis on new triazoles.Pharmacokinetics of itraconazole following oral administration to normal volunteers.Cystic fibrosis and allergic bronchopulmonary aspergillosis.Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.Antifungal prophylaxis following reduced-intensity stem cell transplantation.Amphotericin B lipid complex therapy of experimental fungal infections in miceApplication of ubiquinone systems and electrophoretic comparison of enzymes to identification of clinical isolates of Aspergillus fumigatus and several other species of AspergillusManagement of fungal infections following allogeneic stem cell transplantation.Aspergillosis of the CNS in a pediatric liver transplant recipient: case report and review.Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.New oral treatments for dermatophytosis.Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals.Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patientsReversal of daunorubicin resistance in P388/ADR cells by itraconazole.Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazole.Disseminated aspergillosis due to Aspergillus flavus in an experimental model: efficacy of azole therapy.Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: a comparative in vivo study.In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against Aspergillus species.Treatment of mycoses with itraconazole.Preparation and valuation of a topical solution containing eutectic mixture of itraconazole and phenol.Comparison of in vitro antifungal activity of itraconazole and hydroxy-itraconazole by colorimetric MTT assay.Control of proven pulmonary and suspected CNS aspergillus infection with itraconazole in a patient with chronic granulomatous disease.Itraconazole and multidrug resistance: possible effects on remission rate and disease-free survival in acute leukemia.Molecular dynamics of itraconazole at ambient and high pressure.What is the current place of azoles in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization
P2860
Q24617248-C56DB192-EFBE-4A06-B1F7-D999AB2BFC77Q28379262-49EEDB55-3A38-4C94-882C-509B3422EA4BQ33689767-9D8C6108-CC49-458B-AAB1-3F876D9862BFQ33690036-2EA14823-A22C-4EE9-9959-734A844F73FCQ35072288-6F70F35F-8B66-4436-9995-2AAFA94C28F6Q35077994-EF558094-84F4-4102-AD5B-CE58DD9638F9Q35257842-F3067667-63ED-415F-84C2-1E54AD7586D9Q35287663-D5D8D12D-373F-4F41-BA99-9429063717C0Q35563591-790DF48F-1CCC-40B8-B9DE-E1D831355860Q35624857-A3FA8ACD-1330-437B-8CB0-1B4E486F71F2Q35904922-7B9D8A05-EE67-42DE-8936-C997D172DAEFQ36658236-7C4E0F4F-11BC-4444-AC74-07E25170AAAEQ36753279-BC845DDC-72B9-44DD-8EED-D959F367F658Q37124902-526C27D7-2990-4D9A-8033-F7BB5F824A70Q37202860-F6A7E8BD-732C-4A15-B7D3-2009939D46E7Q37404559-8E5A29E8-43CD-410C-BB03-663543DA6200Q38103889-793CC0B7-AD41-42E1-8843-B271174DC849Q39059013-EDA591AE-1FA3-4E5A-B4BF-D1EBEDA70CE4Q39820429-CBDBFFA5-5C1D-4171-9454-EE69D2616A07Q39866778-1F93332D-D124-44D1-AAE7-2AFB41A9E27AQ40340521-796E056F-889F-478E-A979-12EC60CE0BF2Q43225929-DA4DC5BD-D671-49C2-9FB9-E5F4A03A84FAQ44111055-824CD5D2-FFFD-4D7B-9296-64FFDD97A77CQ44474657-CD02A75A-1C8E-4078-861B-0CCF84920FDCQ45206815-2E58AE14-6543-46E9-918F-36C06A200C6DQ46121627-51A7F49A-5E5C-4194-BD9D-90077228973AQ46575612-87159D4A-6FA9-476E-A782-6090E73649F2Q48110169-CCE30903-1575-416F-85D4-537A5BDAAA43Q48222846-EA9FBEFD-26AD-45EE-8872-83FC1CF2A41FQ48736852-CCFC165F-8D68-43F8-AB61-CCD65FA9F3B2Q54231423-03284294-E1C2-424E-9284-088049E319E7Q54653233-CB067A70-0192-41E2-8DE0-6E09C2DE5253Q57749749-D07E7FF4-5A22-45AE-AA50-0624C3823EA1
P2860
Itraconazole, a new triazole that is orally active in aspergillosis.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Itraconazole, a new triazole that is orally active in aspergillosis.
@en
Itraconazole, a new triazole that is orally active in aspergillosis.
@nl
type
label
Itraconazole, a new triazole that is orally active in aspergillosis.
@en
Itraconazole, a new triazole that is orally active in aspergillosis.
@nl
prefLabel
Itraconazole, a new triazole that is orally active in aspergillosis.
@en
Itraconazole, a new triazole that is orally active in aspergillosis.
@nl
P2093
P2860
P356
P1476
Itraconazole, a new triazole that is orally active in aspergillosis.
@en
P2093
Janssen PA
Van Cutsem J
Van Gerven F
Van de Ven MA
P2860
P304
P356
10.1128/AAC.26.4.527
P407
P577
1984-10-01T00:00:00Z